NanoViricides (NNVC) announced it is forging ahead with its Measles drug development program. The company has commissioned an animal trial to evaluate certain drug candidates, including NV-387, in a lethal animal infection model using specially modified mice. The study will initiate as soon as the animals arrive and are acclimatized. President and Executive Chairman Anil Diwan stated confidence in NV-387’s activity against Measles virus, noting it cured lethal RSV infection in animals. There is no approved drug for Measles infection.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC: